Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of Epstein-Barr virus or human cytomegalovirus in pediatric gliomas: A retrospective single-center study from Tunisia.

Biochemistry and biophysics reports·2026
Same author

Prevalence of Epstein-Barr virus infection in North African cancer patients: a systematic review and meta-analysis protocol.

Systematic reviews·2026
Same author

EZH2-Associated Hypermethylated Gene Signature Predicts Immunotherapy Response and Implicates DUSP5 in Tumor-Immune Regulation in Triple-Negative Breast Cancer.

Cancers·2026
Same author

Clinicopathological significance of microRNA-9 and microRNA-34 methylation in non-small cell lung cancer.

Biochemistry and biophysics reports·2026
Same author

Complete pathological response to neoadjuvant chemoradiotherapy in Crohn's disease-associated fistula adenocarcinoma: a case report.

Frontiers in medicine·2026
Same author

Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 29, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Plasmacytoid bladder cancer: a rare case report.

Wajdi Benabdallah1, Mouna Ben Othmane1, Ines Ouahchi2

  • 1Urology Department.

Annals of Medicine and Surgery (2012)
|May 25, 2023
PubMed
Summary

Plasmacytoid urothelial carcinoma (PUC) of the bladder is a rare, aggressive cancer often diagnosed late. This case highlights its poor prognosis and challenges in treatment, emphasizing the need for further research.

Keywords:
bladder cancercase reportplasmacytoid varianturothelial carcinoma

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Mouse Bladder Wall Injection
03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.2K

Related Experiment Videos

Last Updated: Jul 29, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Mouse Bladder Wall Injection
03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.2K

Area of Science:

  • Uro-oncology
  • Pathology
  • Medical Case Reports

Background:

  • Plasmacytoid urothelial carcinoma (PUC) is a rare variant of bladder cancer.
  • It is associated with late diagnosis and a poor prognosis.
  • Limited treatment guidelines exist due to its rarity.

Purpose of the Study:

  • To report a case of locally advanced PUC.
  • To illustrate the challenges in managing this rare bladder cancer variant.
  • To underscore the aggressive nature and poor outcomes associated with PUC.

Main Methods:

  • Case presentation of a 71-year-old male with gross hematuria.
  • Diagnostic workup included rectal examination and CT scan.
  • Histopathological examination confirmed muscle-invasive PUC.
  • Treatment decision involved palliative chemotherapy.

Main Results:

  • The patient presented with locally advanced, muscle-invasive PUC.
  • The tumor extended to the perivesical fat.
  • Despite palliative chemotherapy, the patient died 6 weeks post-surgery.
  • This case exemplifies the aggressive behavior and poor prognosis of PUC.

Conclusions:

  • PUC of the bladder is characterized by high aggressiveness.
  • Diagnosis typically occurs at an advanced stage.
  • The prognosis for PUC is poor, necessitating further investigation into optimal treatment strategies.